Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Interest Expense
Cost of servicing the company's debt during the period.
Immatics N.V.NASDAQ: IMTX
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of €212K fell 14.9% year over year, behind the -3.5% change in trailing-twelve-month interest expense. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Interest expense amounted to 2.0% of revenue in FY2025, up 1.4 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -14.9% toward the trailing-twelve-month pace of -3.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
EUR · from the income statement
- Latest · FY2025
- 946K EUR
- Year-over-year change
- +6.8%
- 4-year CAGR
- +13.7%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 946K | +6.8% |
| FY2024 | 2024-12-31 | 886K | +6.6% |
| FY2023 | 2023-12-31 | 831K | -19.9% |
| FY2022 | 2022-12-31 | 1.04M | +83.4% |
| FY2021 | 2021-12-31 | 566K | — |
Interest Expense vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.5% is the 4th highest of 9, against a peer median of -14.7%.
- Interest expense amounts to 2.4% of revenue for IMTX, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €18.8M EUR | +27.7% | -4.8% | 0.7% | |
| LTM Sep 2026 | $15.08M USD | -28.5% | +25.6% | 1.1% | |
| LTM Mar 2026 | $11.49M USD | -34.5% | +31.0% | 3.0% | |
| LTM Mar 2026 | $8.49M USD | +11.7% | +28.9% | 12.5% | |
| LTM Mar 2026 | $3.61M USD | -19.5% | +116.6% | 15.6% | |
| LTM Mar 2026 | $2.78M USD | -17.6% | +33.0% | 30.4% | |
| LTM Mar 2026 | $1.38M USD | -11.7% | +8.6% | 3.1% | |
| LTM Mar 2026 | $1.23M USD | +270.1% | — | — | |
| LTM Mar 2026 | €909K EUR | -3.5% | -3.0% | 2.4% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IMTX) | — | -14.7% | +28.9% | 3.0% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.76M | 172.83M | 54M | 155.84M | 48.27M |
| Cost of Revenue | 87.57M | 106.78M | 118.66M | 0 | 0 |
| Gross Profit | (52.81M) | 66.05M | (64.67M) | 155.84M | 48.27M |
| Gross Margin | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| Research & Development | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M |
| Selling, General & Admin | 33.81M | 36.12M | 38.2M | 46.45M | 51.18M |
| Operating Expenses | 121.05M | 142.88M | 155.72M | 194.45M | 230.28M |
| Depreciation & Amortization | 5.47M | 6.84M | 7.23M | 12.23M | 12.4M |
| EBITDA | (87.3M) | 50.04M | (88.93M) | 34.46M | (185.09M) |
| EBITDA Margin | -251.1% | 29.0% | -164.7% | 22.1% | -383.5% |
| Operating Income | (86.29M) | 29.95M | (101.73M) | (38.62M) | (182.02M) |
| Operating Margin | -248.2% | 17.3% | -188.4% | -24.8% | -377.1% |
| Interest Income | 133K | 2.48M | 13.85M | 25M | 17.18M |
| Interest Expense | 566K | 1.04M | 831K | 886K | 946K |
| Other Income / Expenses | (7.04M) | 12.08M | 4.73M | 59.96M | (16.42M) |
| Income Before Tax | (93.34M) | 42.04M | (96.99M) | 21.35M | (198.44M) |
| Pre-Tax Margin | -268.5% | 24.3% | -179.6% | 13.7% | -411.1% |
| Income Tax Expense | 0 | 4.55M | 0 | 6.13M | (1.99M) |
| Net Income | (95.06M) | 37.51M | (96.99M) | 15.22M | (196.45M) |
| Net Margin | -273.5% | 21.7% | -179.6% | 9.8% | -407.0% |
| EPS (Basic) | (1.51) | 0.55 | (1.20) | 0.14 | (1.54) |
| EPS (Diluted) | (1.51) | 0.54 | (1.20) | 0.14 | (1.54) |
| Weighted Avg Shares | 62.91M | 67.22M | 80.55M | 108.7M | 122.35M |
| Weighted Avg Shares (Diluted) | 62.91M | 68.82M | 80.55M | 106.8M | 122.35M |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.